Actavis divests its distribution business in Bulgaria
Actavis has announced the divestment of its Bulgarian distribution company, Higia EAD, to a local private investor, Rossitsa Veselinova Velikova.
This decision is a result of the detailed business review conducted on global and local level in 2009. Actavis continues to focus its efforts on its core business, the development, production and sale of high-quality generic pharmaceuticals.
Iliya Pashov, Executive director of Actavis Bulgaria: “Actavis is the biggest pharmaceutical company in Bulgaria in terms of sales and production. Our future plans are to focus on Actavis’ core business and that does not include distribution. Among a number of offers received we chose the best one, not only for Actavis but for the employees of Higia and its future growth on the local distribution market. Actavis will continue working with Higia and the other pharmaceutical distributors in Bulgaria.”
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
John_Dix_Fisher
Echis_megalocephalus
Organon Involved in Unique Initiative for the Development and Production of Biopharmaceutical Medicines

Soil bacteria as biocatalysts - Researchers have clarified the molecular structure of an enzyme class, enabling them to use bacteria to produce prodrugs
Galapagos and Arthrogen enter target discovery alliance

Time-switch for immune cells
Canadian_Deaf_Theatre
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
Orange_G
